SAGE Therapeutics (NASDAQ:SAGE) announced its earnings results on Tuesday. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.41) by ($0.22), Fidelity Earnings reports. During the same period last year, the company earned ($1.97) earnings per share.
Shares of SAGE traded up $1.16 during trading hours on Thursday, hitting $131.15. The stock had a trading volume of 2,242 shares, compared to its average volume of 469,811. The company has a market cap of $5.99 billion, a PE ratio of -18.64 and a beta of 2.76. SAGE Therapeutics has a 1-year low of $61.67 and a 1-year high of $195.97.
A number of analysts have weighed in on the company. BidaskClub downgraded SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, September 15th. Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a report on Monday, October 29th. Morgan Stanley increased their price target on SAGE Therapeutics from $228.00 to $230.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Canaccord Genuity set a $220.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 1st. Finally, Piper Jaffray Companies assumed coverage on SAGE Therapeutics in a report on Monday, August 6th. They set an “overweight” rating and a $206.00 price target for the company. One investment analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $204.06.
TRADEMARK VIOLATION WARNING: “SAGE Therapeutics (SAGE) Announces Quarterly Earnings Results, Misses Estimates By $0.22 EPS” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2018/11/08/sage-therapeutics-sage-announces-quarterly-earnings-results-misses-estimates-by-0-22-eps.html.
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Featured Article: How are the companies in the S&P 500 selected?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.